(BLFS) BioLife Solutions - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.209m USD | Total Return: 8% in 12m
Avg Turnover: 7.37M
Qual. Beats: 0
Rev. Trend: -62.8%
Qual. Beats: 0
Warnings
High Debt/EBITDA (7.2) with thin interest coverage (-9.1)
High Debt while negative Cash Flow
Interest Coverage Ratio -9.1 is critical
Altman Z'' -13.48 < 1.0 - financial distress zone
Choppy
Tailwinds
Confidence
BioLife Solutions, Inc. (NASDAQ: BLFS) specializes in the development and manufacturing of bioproduction tools and services tailored for the cell and gene therapy (CGT) market. Its core portfolio includes proprietary biopreservation media, such as HypoThermosol and CryoStor, designed to maintain cell viability during storage and transport. The company also provides automated thawing devices, closed-system vials, and cloud-connected thermal shipping containers to support the end-to-end biologic supply chain.
The CGT sector relies heavily on cold chain logistics, where specialized media and hardware are essential to prevent cellular degradation during the transition from laboratory to patient. BioLife operates on a consumable-heavy business model, where its media products are often integrated into customers regulatory filings, creating high switching costs and recurring revenue streams as therapies move toward commercialization. Investors can further evaluate these industry dynamics and valuation metrics by exploring the data available on ValueRay.
Headquartered in Bothell, Washington, the company serves a global client base across research institutions and pharmaceutical manufacturers. By focusing on standardized, automated tools for cell processing and transport, BioLife addresses critical bottlenecks in the manufacturing of complex biologic-based therapies.
- Cell and gene therapy clinical trial volume drives biopreservation media revenue growth
- Shift toward high-margin recurring consumables improves overall corporate gross margins
- Divestiture of freezer and cooling businesses streamlines focus on core bioprocessing
- Global expansion of commercialized biologic therapies increases demand for proprietary media
- Regulatory approvals for new regenerative medicines expand the total addressable market size
| Net Income: -10.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -3.30 > 1.0 |
| NWC/Revenue: 115.2% < 20% (prev 146.0%; Δ -30.82% < -1%) |
| CFO/TA 0.04 > 3% & CFO 17.9m > Net Income -10.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.2m) vs 12m ago 4.48% < -2% |
| Gross Margin: 63.89% > 18% (prev 0.50%; Δ 6.34k% > 0.5%) |
| Asset Turnover: 25.07% > 50% (prev 17.92%; Δ 7.15% > 0%) |
| Interest Coverage Ratio: -9.12 > 6 (EBITDA TTM -7.46m / Interest Expense TTM 1.34m) |
| A: 0.29 (Total Current Assets 133.2m - Total Current Liabilities 18.3m) / Total Assets 400.9m |
| B: -0.84 (Retained Earnings -338.5m / Total Assets 400.9m) |
| C: -0.03 (EBIT TTM -12.3m / Avg Total Assets 398.0m) |
| D: -11.81 (Book Value of Equity -338.6m / Total Liabilities 28.7m) |
| Altman-Z'' = -13.48 = D |
| DSRI: 1.01 (Receivables 13.1m/9.17m, Revenue 99.8m/70.8m) |
| GMI: 0.79 (GM 63.89% / 50.39%) |
| AQI: 0.98 (AQ_t 0.61 / AQ_t-1 0.63) |
| SGI: 1.41 (Revenue 99.8m / 70.8m) |
| TATA: -0.07 (NI -10.5m - CFO 17.9m) / TA 400.9m) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 24.03 with a total of 747,277 shares traded.
Over the past week, the price has changed by +7.76%,
over one month by +12.24%,
over three months by +6.90% and
over the past year by +7.95%.
BioLife Solutions has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy BLFS.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 32.3 | 34.4% |
P/E Forward = 188.6792
P/S = 11.89
P/B = 3.2486
P/EG = 65.3833
Revenue TTM = 99.8m USD
EBIT TTM = -12.3m USD
EBITDA TTM = -7.46m USD
Long Term Debt = 10.0m USD (estimated: total debt 14.9m - short term 4.82m)
Short Term Debt = 4.82m USD (from shortTermDebt, last quarter)
Debt = 27.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.4m
Net Debt = -53.8m USD (calculated: Debt 27.2m - CCE 81.0m)
Enterprise Value = 1.15b USD (1.21b + Debt 27.2m - CCE 81.0m)
Interest Coverage Ratio = -9.12 (Ebit TTM -12.3m / Interest Expense TTM 1.34m)
EV/FCF = -643.8x (Enterprise Value 1.15b / FCF TTM -1.79m)
FCF Yield = -0.16% (FCF TTM -1.79m / Enterprise Value 1.15b)
FCF Margin = -1.80% (FCF TTM -1.79m / Revenue TTM 99.8m)
Net Margin = -10.52% (Net Income TTM -10.5m / Revenue TTM 99.8m)
Gross Margin = 63.89% ((Revenue TTM 99.8m - Cost of Revenue TTM 36.0m) / Revenue TTM)
Gross Margin QoQ = 63.31% (prev 67.48%)
Tobins Q-Ratio = 2.88 (Enterprise Value 1.15b / Total Assets 400.9m)
Interest Expense / Debt = 4.94% (Interest Expense 1.34m / Debt 27.2m)
Taxrate = 4.97% (62.0k / 1.25m)
NOPAT = -11.7m (EBIT -12.3m * (1 - 4.97%)) [loss with tax shield]
Current Ratio = 7.30 (Total Current Assets 133.2m / Total Current Liabilities 18.3m)
Debt / Equity = 0.07 (Debt 27.2m / totalStockholderEquity, last quarter 372.2m)
Debt / EBITDA = 7.21 (negative EBITDA) (Net Debt -53.8m / EBITDA -7.46m)
Debt / FCF = 29.98 (negative FCF - burning cash) (Net Debt -53.8m / FCF TTM -1.79m)
Total Stockholder Equity = 361.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.64% (Net Income -10.5m / Total Assets 400.9m)
RoE = -1.50% (Net Income TTM -10.5m / Total Stockholder Equity 699.8m)
RoCE = -1.73% (EBIT -12.3m / Capital Employed (Equity 699.8m + L.T.Debt 10.0m))
RoIC = -3.80% (negative operating profit) (NOPAT -11.7m / Invested Capital 306.5m)
WACC = 10.04% (E(1.21b)/V(1.24b) * Re(10.16%) + D(27.2m)/V(1.24b) * Rd(4.94%) * (1-Tc(0.05)))
Discount Rate = 10.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 4.27%
[DCF] Fair Price = unknown (Cash Flow -1.79m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: -62.80 | Revenue CAGR: -18.02% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.06 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.07 | Chg30d=+75.00% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=0.25 | Chg30d=+85.19% | Revisions=-20% | GrowthEPS=+91.9% | GrowthRev=+18.2%
EPS next Year (2027-12-31): EPS=0.29 | Chg30d=+0.00% | Revisions=+20% | GrowthEPS=+16.0% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: -20%